Studies have demonstrated that using PARP inhibitors in cancer cells carrying mutations in BRCA1 or BRCA2 could develop resistance by acquiring secondary mutations in the BRCA genes that, interestingly, reverse the effect of the original mutation, restoring the levels of functional BRCA proteins [137,138]. Here, PARP1 is linked to cancer.